Last reviewed · How we verify
Acnatac® Gel right face
Acnatac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial and keratolytic agent) to reduce acne-causing bacteria and promote skin cell turnover.
Acnatac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial and keratolytic agent) to reduce acne-causing bacteria and promote skin cell turnover. Used for Acne vulgaris.
At a glance
| Generic name | Acnatac® Gel right face |
|---|---|
| Also known as | Clindamycin 1%, Tretinoin 0,025% |
| Sponsor | GWT-TUD GmbH |
| Drug class | Topical antibiotic combination |
| Target | Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin inhibits bacterial protein synthesis, reducing Cutibacterium acnes (formerly Propionibacterium acnes) proliferation. Benzoyl peroxide generates reactive oxygen species that kill bacteria and help unclog pores by promoting desquamation. The combination addresses both bacterial and comedonal components of acne.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation/erythema
- Dryness
- Peeling
- Contact dermatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acnatac® Gel right face CI brief — competitive landscape report
- Acnatac® Gel right face updates RSS · CI watch RSS
- GWT-TUD GmbH portfolio CI